Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
1. LLY launches high-dose Zepbound vials for self-pay patients. 2. New vial pricing lowers costs for Medicare and uninsured individuals. 3. Expanded supply meets soaring demand and counters compounded alternatives. 4. Switch from autoinjector pens eases production and improves distribution.